Identification of microRNA 885-5p as a novel regulator of tumor metastasis by targeting CPEB2 in colorectal cancer

Lam, Carol S. F.; Ng, Lui; Chow, Albert H.L.; Wan, Timothy Ming‐Hun; Yau, Simon; Cheng, Nathan Shiu-Man; Wong, Sunny Kit-Man; Man, Johnny Hon-Wai; Lo, Oswens Siu-Hung; Foo, Chi Chung; Poon, Jensen T. C.; Pang, Roberta; Law, Wai‐Lun

doi:10.18632/oncotarget.15844

Cited by 34 publications

(26 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, miR-885-5p has been reported to target cyclin-dependent kinase 2 and minichromosome maintenance complex component 5, activate cellular tumor antigen p53, and inhibit neuroblastoma proliferation and survival (24). Although previous work indicated that miR-885-5p was significantly upregulated in liver metastasis and colorectal cancer, and activated epithelial-to-mesenchymal transition (25), it was hypothesized that miR-885-5p may interact with alternative proteins and serve different functions in liver metastasis and colorectal cancer.…”

Section: Discussionmentioning

confidence: 99%

miR‑885‑5p suppresses osteosarcoma proliferation, migration and invasion through regulation of β‑catenin

Liu

Bao²,

Tian³

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

MicroRNAs (miRs) have been reported to serve key roles in cancer. To investigate the function of miR-885-5p in osteosarcoma, the expression levels of miR-885-5p were analyzed in 85 osteosarcoma tissue samples and adjacent non-cancerous tissue samples, using reverse transcription-quantitative polymerase chain reaction analysis. It was demonstrated that miR-885-5p was downregulated in osteosarcoma tissues and cell lines. Notably, the expression level of miR-885-5p was closely associated with tumor size, Tumor-Node-Metastasis stage and lymph node metastasis. Additionally, low expression levels of miR-885-5p also predicted a poor prognosis of osteosarcoma. To further decipher the roles of miR-885-5p in osteosarcoma, it was determined that β-catenin, a key component of the Wnt signaling pathway, was a target of miR-885-5p. Furthermore, several functional experiments, including a colony formation assay, CCK-8 assay, wound healing assay and Transwell invasion assay, revealed that miR-885-5p suppressed cell proliferation, migration and invasion through inhibition of β-catenin. The results of the present study provide a novel insight into the molecular roles of miR-885-5p in osteosarcoma.

show abstract

Section: Discussionmentioning

confidence: 99%

miR‑885‑5p suppresses osteosarcoma proliferation, migration and invasion through regulation of β‑catenin

Liu

Bao²,

Tian³

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

show abstract

“… 9 , 10 Moreover, miRNAs are validated to be intricately involved in the regulation of tumor metastasis and epithelial-mesenchymal transition. 11 , 12 , 13 , 14 , 15 , 16 MicroRNA-106a-5p (MiR-106a-5p), a member of the miR-17 family, has been reported to be aberrantly regulated in a diversity of tumors. It is considerably downregulated and proved to exert tumor suppressor effects in astrocytoma, osteosarcoma and colorectal cancer.…”

mentioning

confidence: 99%

MiR-106a-5p inhibits the cell migration and invasion of renal cell carcinoma through targeting PAK5

Pan

Wei

et al. 2017

Cell Death Dis

View full text Add to dashboard Cite

MicroRNA-106a-5p (MiR-106a-5p), a small non-coding RNA, has been reported to be downregulated in astrocytoma, osteosarcoma and colorectal cancer. However, the expression levels and biological function in renal cell carcinoma (RCC) have not been studied yet. In this study, we found that the miR-106a-5p was significantly downregulated in RCC tissues and cell lines, and that overexpression of miR-106a-5p led to decreased cell metastasis ability in a xenograft model. Inhibition of miR-106a-5p in RCC cell lines altered the cell migration, invasion and wound healing abilities. Mechanistic studies demonstrated that miR-106a-5p directly bound to the 3′-UTR of the PAK5 mRNA and mediated a decrease in the protein expression of PAK5. We further proved that PAK5 protein levels were negatively correlated with the miR-106a-5p expression in both patient samples and xenograft model. In epigenetics, methylation specific PCR experiments indicated that the upstream gene promoter of miR-106a-5p was hypermethylated in RCC, which might be responsible for its downregulation. Our findings suggested that miR-106a-5p might be a potential gene therapy target for the treatment of RCC metastasis.

show abstract

“…Upregulation of this microRNA has been linked to enhanced proliferation and migration [33], and the development of liver and lung metastases in colorectal cancer. [34] In contrast, miR-885-5p suppressed proliferation, migration and invasion in vitro in osteosarcoma cells, and was downregulated in osteosarcoma patients with low expression levels being associated with a poor prognosis. [35] In our study, miR-885-5p was downregulated in the recurrent tumors, possibly matching the findings in osteosarcoma with low levels of miR-885-5p being associated with more proliferation and a poorer prognosis.…”

Section: Discussionmentioning

confidence: 94%

MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma

et al. 2020

View full text Add to dashboard Cite

Approximately one-third of the patients with well-differentiated liposarcoma (WDLPS) will develop a local recurrence. Not much is known about the molecular relationship between the primary tumor and the recurrent tumor, which is important to reveal potential drivers of recurrence. Here we investigated the biology of recurrent WDLPS by comparing paired primary and recurrent WDLPS using microRNA profiling and genome-wide DNA methylation analyses. In total, 27 paired primary and recurrent WDLPS formalin-fixed and paraffinembedded tumor samples were collected. MicroRNA expression profiles were determined using TaqMan ® Low Density Array (TLDA) cards. Genome-wide DNA methylation and differentially methylated regions (DMRs) were assessed by methylated DNA sequencing (MeD-seq). A supervised cluster analysis based on differentially expressed microRNAs between paired primary and recurrent WDLPS did not reveal a clear cluster pattern separating the primary from the recurrent tumors. The clustering was also not based on tumor localization, time to recurrence, age or status of the resection margins. Changes in DNA methylation between primary and recurrent tumors were extremely variable, and no consistent DNA methylation changes were found. As a result, a supervised clustering analysis based on DMRs between primary and recurrent tumors did not show a distinct cluster pattern based on any of the features. Subgroup analysis for tumors localized in the extremity or the retroperitoneum also did not yield a clear distinction between primary and recurrent WDLPS samples. In conclusion, microRNA expression profiles and DNA methylation profiles do not distinguish between primary and recurrent WDLPS and no putative common drivers could be identified.

show abstract

Identification of microRNA 885-5p as a novel regulator of tumor metastasis by targeting CPEB2 in colorectal cancer

Cited by 34 publications

References 43 publications

miR‑885‑5p suppresses osteosarcoma proliferation, migration and invasion through regulation of β‑catenin

miR‑885‑5p suppresses osteosarcoma proliferation, migration and invasion through regulation of β‑catenin

MiR-106a-5p inhibits the cell migration and invasion of renal cell carcinoma through targeting PAK5

MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma

Contact Info

Product

Resources

About